REG - Yourgene Health PLC - Close of Retail Offer

Yourgene HealthAnnouncement

06/01/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230106:nRSF9564La&default-theme=true

RNS Number : 9564L  Yourgene Health PLC  06 January 2023

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND,
CANADA, THE REPUBLIC OF SOUTH AFRICA OR JAPAN OR ANY OTHER JURISDICTION IN
WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU
REGULATION 2014/596/EU (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE
EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.

 

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Close of Retail Offer

 

Yourgene Health plc (AIM: YGEN), a leading international molecular diagnostics
group, announces that, further to the announcement made at 11:00 a.m. on 22
December 2022, the Retail Offer conducted via the BookBuild platform has now
closed.

 

The results of the Retail Offer and the resulting total voting rights in the
Company's shares will both be confirmed following the conclusion of the
General Meeting of the Company to be held at 4.00 p.m. on 9 January 2023.

 

Admission of the Second Admission Shares to be issued under the Retail Offer
is expected to take place at 8.00 a.m. on 11 January 2023. Completion of the
Retail Offer is conditional, inter alia, upon the completion of the Placing.

 

Capitalised terms used in this announcement have the meanings given to them in
the Circular published on 23 December 2022, unless the context provides
otherwise.

 

Enquiries:

 Yourgene Health plc                                      Tel: +44 (0) 161 699 8122

 Lyn Rees (Chief Executive Officer)                       investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall (Chief Financial Officer)
 Joanne Cross (Director of Marketing)

 Cairn Financial Advisers LLP (NOMAD)                     Tel: +44 (0) 20 7213 0880
 Liam Murray/ James Caithie/ Ludovico Lazzaretti

 Singer Capital Markets (Corporate Broker)                Tel: +44 (0) 20 7496 3000
 Aubrey Powell/ Tom Salvesen/ George Tzimas/ Alex Emslie

 Walbrook PR Ltd (Media and Investor Relations)           Tel: +44 (0)20 7933 8780 or

                                                          yourgene@walbrookpr.com
 Paul McManus/ Lianne Applegarth/ Alice Woodings          Mob: 07980 541 893 / 07584 391 303 / 07407 804 654

 

 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID-19 testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCNKABNKBKDCDK